(E/Z) -SU9516

• Description:

  (E/Z) -SU9516 is the isomer of SU9516 (HY-18629) . SU9516 is a potent CDK2 inhibitor, with an IC50 of 22 nM, and also shows inhibitory effects on CDK1 and CDK4, with IC50s of 40, 200 nM, respectively.

• UNSPSC:

  12352005

• Hazard Statement:

  H302-H315-H319-H335

• Target:

  Apoptosis; Autophagy; CDK

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Autophagy; Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/e-z-su9516.html

• Smiles:

  O=C1NC2=C(C=C(OC)C=C2)/C1=C\C3=CN=CN3

• Molecular Formula:

  C13H11N3O2

• Molecular Weight:

  241.25

• Precautions:

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

• References & Citations:

  [1]Lane ME, et al. A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Res. 2001 Aug 15;61 (16) :6170-7.|[2]Yu B, et al. SU9516, a cyclin-dependent kinase 2 inhibitor, promotes accumulation of high molecular weight E2F complexes in human colon carcinoma cells. Biochem Pharmacol. 2002 Oct 1;64 (7) :1091-100.|[3]Gao N, et al. The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1- (3H-imidazol-4-yl) -meth- (Z) -ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanism. Mol Pharmacol. 2006 Aug;70 (2) :645-55.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  666837-93-0